In parallel, a bimodulation assay with a highly-active ABCG2 chromone derivative inhibitor (MBL-II-141) (Honorat, M., et al.Oncotarget 2014, 5, 11957–11970) was performed to sensitize tumor growth to the ABCG2 substrate irinotecan. The gene discussed is ABCG2; the disease is neoplasm.